-
Journal Context: The Lancet / PubMed | Identifiers: DOI: 10.1016/S0140-6736(14)61855-0 / PMID: 25743952
-
Methodology: Parallel multicenter Phase III human clinical trials conducted across Europe and the United States, enrolling adult patients presenting with Erythropoietic Protoporphyria (EPP—a rare genetic disorder causing severe, painful phototoxicity upon minor light exposure). Subjects received a subcutaneous biodegradable implant containing $16\text{ mg}$ of active MT-1 or a placebo at 2-month intervals to monitor pain-free sun exposure duration and track systemic safety profiles.
-
Key Findings: MT-1 functioned as an exceptional photoprotective agent. Patients treated with active Afamelanotide experienced a statistically significant increase in pain-free time spent outdoors in direct sunlight and reported vastly superior quality-of-life scores compared to the control group. The peptide successfully drove localized eumelanin synthesis, providing a physical “neutral density filter” that absorbs and scatters light waves. This study formed the primary clinical data that secured formal US FDA approval for MT-1 under the non-proprietary index Afamelanotide.
